CNS response to a second pro-inflammatory event depends on whether the primary demyelinating lesion is active or resolved

Brain, Behavior, and Immunity

Volumn 26, Issue 7, 2012, Pages 1102-1115

  Murta, Veronica ^a   Pitossi, Fernando J ^a   Ferrari, Carina C ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Cytokines; Demyelination; IL 1 ; IL 1R1; Inflammation; Microglia; Relapse

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; INTERLEUKIN 1BETA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AXONAL INJURY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DEMYELINATING DISEASE; INFLAMMATION; MACROPHAGE; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REMYELINIZATION; STIMULUS RESPONSE;

ANIMALS; AXONS; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; DEPENDOVIRUS; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-1BETA; MALE; NEOSTRIATUM; NEUROGLIA; NEUTROPHILS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-1; RECURRENCE; RNA; STEREOTAXIC TECHNIQUES;

EID: 84865647696     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.07.007     Document Type: Article

References (86)

1. Aggelakis K., Zacharaki F., Dardiotis E., Xiromerisiou G., Tsimourtou V., Ralli S., Gkaraveli M., Bourpoulas D., Rodopoulou P., Papadimitriou A., Hadjigeorgiou G. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS. Neurol. Sci. 2010, 31:253-257.
2. Andersson P.B., Perry V.H., Gordon S. Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. J. Exp. Med. 1992, 176:255-259.
3. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 1997, 23:406-415.
4. Argaw A.T., Zhang Y., Snyder B.J., Zhao M.L., Kopp N., Lee S.C., Raine C.S., Brosnan C.F., John G.R. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J. Immunol. 2006, 177:5574-5584.
5. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123(Pt 6):1174-1183.
6. Blakemore W.F., Franklin R.J. Remyelination in experimental models of toxin-induced demyelination. Curr. Top. Microbiol. Immunol. 2008, 318:193-212.
7. Blond D., Campbell S.J., Butchart A.G., Perry V.H., Anthony D.C. Differential induction of interleukin-1beta and tumour necrosis factor-alpha may account for specific patterns of leukocyte recruitment in the brain. Brain Res. 2002, 958:89-99.
8. Borzani I., Tola M.R., Caniatti L., Collins A., De Santis G., Luiselli D., Mamolini E., Scapoli C. The interleukin-1 cluster gene region is associated with multiple sclerosis in an Italian Caucasian population. Eur. J. Neurol. 2010, 17:930-938.
9. Bramow S., Frischer J.M., Lassmann H., Koch-Henriksen N., Lucchinetti C.F., Sorensen P.S., Laursen H. Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010, 133:2983-2998.
10. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995, 45:S16-21.
11. Cannon J.G., Dinarello C.A. Increased plasma interleukin-1 activity in women after ovulation. Science 1985, 227:1247-1249.
12. Carlson T., Kroenke M., Rao P., Lane T.E., Segal B. The Th17-ELR+CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J. Exp. Med. 2008, 205:811-823.
13. Codarri L., Fontana A., Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr. Opin. Neurol. 2010, 23:205-211.
14. Colditz I.G. Kinetics of tachyphylaxis to mediators of acute inflammation. Immunology 1985, 55:149-156.
15. Comi G., Filippi M. Clinical trials in multiple sclerosis: methodological issues. Curr. Opin. Neurol. 2005, 18:245-252.
16. Cybulsky M.I., McComb D.J., Movat H.Z. Neutrophil leukocyte emigration induced by endotoxin. Mediator roles of interleukin 1 and tumor necrosis factor alpha 1. J. Immunol. 1988, 140:3144-3149.
17. Ching S., He L., Lai W., Quan N. IL-1 type I receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system. Brain Behav. Immun. 2005, 19:127-137.
18. Ching S., Zhang H., Belevych N., He L., Lai W., Pu X.A., Jaeger L.B., Chen Q., Quan N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci. 2007, 27:10476-10486.
19. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011, 18:21-29.
20. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., del Rey A., Pitossi F.J., Oertel W.H. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 2003, 18:2731-2742.
21. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
22. Dincic E., Zivkovic M., Stankovic A., Obradovic D., Alavantic D., Kostic V., Raicevic R. Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J. Neuroimmunol. 2006, 177:146-150.
23. Docagne F., Campbell S.J., Bristow A.F., Poole S., Vigues S., Guaza C., Perry V.H., Anthony D.C. Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur. J. Neurosci. 2005, 21:1205-1214.
24. Dujmovic I., Mangano K., Pekmezovic T., Quattrocchi C., Mesaros S., Stojsavljevic N., Nicoletti F., Drulovic J. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J. Neuroimmunol. 2009, 207:101-106.
25. Edwards L.J., Sharrack B., Ismail A., Tumani H., Constantinescu C.S. Central inflammation versus peripheral regulation in multiple sclerosis. J. Neurol. 2011, 258:1518-1527.
26. Ericsson A., Liu C., Hart R.P., Sawchenko P.E. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J. Comp. Neurol. 1995, 361:681-698.
27. Ferrari C.C., Depino A.M., Prada F., Muraro N., Campbell S., Podhajcer O., Perry V.H., Anthony D.C., Pitossi F.J. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am. J. Pathol. 2004, 165:1827-1837.
28. Furlan R., Bergami A., Brambilla E., Butti E., De Simoni M.G., Campagnoli M., Marconi P., Comi G., Martino G. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 2007, 14:93-98.
29. Hagemeier K., Bruck W., Kuhlmann T. Multiple sclerosis - remyelination failure as a cause of disease progression. Histol. Histopathol. 2012, 27:277-287.
30. Haines J.D., Inglese M., Casaccia P. Axonal damage in multiple sclerosis. Mt Sinai J. Med. 2011, 78:231-243.
31. Hartung H.P., Kieseier B.C., Hemmer B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J. Neurol. 2005, 252(Suppl 5):v30-v37.
32. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990, 40:1735-1739.
33. Hiremath M.M., Chen V.S., Suzuki K., Ting J.P., Matsushima G.K. MHC class II exacerbates demyelination in vivo independently of T cells. J. Neuroimmunol. 2008, 203:23-32.
34. Hohlfeld, R., Kerschensteiner, M., Stadelmann, C., Lassmann, H., Wekerle, H., 2005. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Ernst Schering Res Found Workshop, 23-38.
35. Holman D.W., Klein R.S., Ransohoff R.M. The blood-brain barrier, chemokines and multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:220-230.
36. Howe C.L., Mayoral S., Rodriguez M. Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1beta. Neurobiol. Dis. 2006, 23:731-739.
37. Huitinga I., van der Cammen M., Salm L., Erkut Z., van Dam A., Tilders F., Swaab D. IL-1beta immunoreactive neurons in the human hypothalamus: reduced numbers in multiple sclerosis. J. Neuroimmunol. 2000, 107:8-20.
38. Irvine K.A., Blakemore W.F. Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J. Neuroimmunol. 2006, 175:69-76.
39. Kanwar J.R. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr. Med. Chem. 2005, 12:2947-2962.
40. Kieseier B.C., Hemmer B., Hartung H.P. Multiple sclerosis-novel insights and new therapeutic strategies. Curr. Opin. Neurol. 2005, 18:211-220.
41. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000, 157:267-276.
42. Kotter M.R., Setzu A., Sim F.J., Van Rooijen N., Franklin R.J. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001, 35:204-212.
43. Kotter M.R., Zhao C., van Rooijen N., Franklin R.J. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol. Dis. 2005, 18:166-175.
44. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002, 125:2202-2212.
45. Li Q., Powell N., Zhang H., Belevych N., Ching S., Chen Q., Sheridan J., Whitacre C., Quan N. Endothelial IL-1R1 is a critical mediator of EAE pathogenesis. Brain Behav. Immun. 2011, 25:160-167.
46. Li W.W., Setzu A., Zhao C., Franklin R.J. Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J. Neuroimmunol. 2005, 158:58-66.
47. Lindquist S., Hassinger S., Lindquist J.A., Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Mult. Scler. 2011, 17:851-866.
48. Liu L., Belkadi A., Darnall L., Hu T., Drescher C., Cotleur A.C., Padovani-Claudio D., He T., Choi K., Lane T.E., Miller R.H., Ransohoff R.M. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 2010, 13:319-326.
49. Loma I., Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr. Neuropharmacol. 2011, 9:409-416.
50. Lucchinetti C.F., Bruck W., Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol. 2004, 56:308.
51. Ludigs, K., Parfenov, V., Du Pasquier, R.A., Guarda, G., 2012. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cell. Mol. Life Sci.
52. Mancardi G., Hart B., Roccatagliata L., Brok H., Giunti D., Bontrop R., Massacesi L., Capello E., Uccelli A. Demyelination and axonal damage in a non-human primate model of multiple sclerosis. J. Neurol. Sci. 2001, 184:41-49.
53. Mason J.L., Suzuki K., Chaplin D.D., Matsushima G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 2001, 21:7046-7052.
54. Matsuki T., Nakae S., Sudo K., Horai R., Iwakura Y. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 2006, 18:399-407.
55. Merson T.D., Binder M.D., Kilpatrick T.J. Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. Neuromol. Med. 2010, 12:99-132.
56. Moreno B., Jukes J.P., Vergara-Irigaray N., Errea O., Villoslada P., Perry V.H., Newman T.A. Systemic inflammation induces axon injury during brain inflammation. Ann. Neurol. 2011, 70:932-942.
57. Naegele, M., Tillack, K., Reinhardt, S., Schippling, S., Martin, R., Sospedra, M., 2011. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J. Neuroimmunol.
58. Patrikios P., Stadelmann C., Kutzelnigg A., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Bruck W., Lucchinetti C., Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-3172.
59. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, Orlando, FL.
60. Penderis J., Shields S.A., Franklin R.J. Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. Brain 2003, 126:1382-1391.
61. Perry V.H., Cunningham C., Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 2007, 7:161-167.
62. Pober J.S., Bevilacqua M.P., Mendrick D.L., Lapierre L.A., Fiers W., Gimbrone M.A. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J. Immunol. 1986, 136:1680-1687.
63. Popescu B.F., Lucchinetti C.F. Pathology of demyelinating diseases. Annu. Rev. Pathol. 2012, 7:185-217.
64. Prineas J.W., Barnard R.O., Revesz T., Kwon E.E., Sharer L., Cho E.S. Multiple sclerosis. Pathology of recurrent lesions. Brain 1993, 116(Pt 3):681-693.
65. Raine C.S., Cross A.H. Axonal dystrophy as a consequence of long-term demyelination. Lab. Invest. 1989, 60:714-725.
66. Rothwell N.J., Luheshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000, 23:618-625.
67. Ruggiero V. Involvement of IL-1R/TLR signalling in experimental autoimmune encephalomyelitis and multiple sclerosis 2011, Curr. Mol. Med.
68. Sarial S., Shokrgozar M.A., Amirzargar A., Shokri F., Radfar J., Zohrevand P., Arjang Z., Sahraian M.A., Lotfi J. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran. J. Allergy Asthma Immunol. 2008, 7:37-40.
69. Saura J., Pares M., Bove J., Pezzi S., Alberch J., Marin C., Tolosa E., Marti M.J. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. J. Neurochem. 2003, 85:651-661.
70. Schiffenbauer J., Streit W.J., Butfiloski E., LaBow M., Edwards C., Moldawer L.L. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin. Immunol. 2000, 95:117-123.
71. Shaftel S.S., Carlson T.J., Olschowka J.A., Kyrkanides S., Matousek S.B., O'Banion M.K. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J. Neurosci. 2007, 27:9301-9309.
72. Simi A., Tsakiri N., Wang P., Rothwell N.J. Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 2007, 35:1122-1126.
73. Soulika A.M., Lee E., McCauley E., Miers L., Bannerman P., Pleasure D. Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J. Neurosci. 2009, 29:14965-14979.
74. Stern E.L., Quan N., Proescholdt M.G., Herkenham M. Spatiotemporal induction patterns of cytokine and related immune signal molecule mRNAs in response to intrastriatal injection of lipopolysaccharide. J. Neuroimmunol. 2000, 109:245-260.
75. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1685-1691.
76. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
77. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 1991, 104:230-234.
78. Turrin N.P., Gayle D., Ilyin S.E., Flynn M.C., Langhans W., Schwartz G.J., Plata-Salaman C.R. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res. Bull. 2001, 54:443-453.
79. Ulich T.R., Guo K.Z., Irwin B., Remick D.G., Davatelis G.N. Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression. Am. J. Pathol. 1990, 137:1173-1185.
80. Wang, X., Barone, F.C., Aiyar, N.V., Feuerstein, G.Z., 1997. Interleukin-1 receptor and receptor antagonist gene expression after focal stroke in rats. Stroke 28, 155-161 (discussion 161-152).
81. Warabi Y. Role of IL-1 and potential therapies in multiple sclerosis. Drug Discovery Today: Ther. Strategies 2007, 4:19-24.
82. Watzlawik J., Warrington A.E., Rodriguez M. Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination. Expert Rev. Neurother. 2010, 10:441-457.
83. Yang X.F., Wang H., Wen L. From myelin debris to inflammatory responses: a vicious circle in diffuse axonal injury. Med. Hypotheses 2011, 77:60-62.
84. Ysrraelit M.C., Gaitan M.I., Lopez A.S., Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008, 71:1948-1954.
85. Zeis T., Graumann U., Reynolds R., Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008, 131:288-303.
86. Zivadinov R., Pirko I. Advances in understanding gray matter pathology in multiple sclerosis: are we ready to redefine disease pathogenesis?. BMC Neurol. 2012, 12:9.